Moderna Forecast, price target & analysts
Why the stock moved Beta
Moderna Target price 2026 - Analyst rating & recommendation
Moderna Classifications & Recommendation
Moderna Price Target
| Target Price | $124.95 |
| Price | $158.07 |
| Deviation |
20.95%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Moderna 2027 .
The average Moderna target price is $124.95.
This is
20.95%
register free of charge
$178.50
12.92%
register free of charge
$40.40
74.44%
register free of charge
|
|
| A rating was issued by 30 analysts: 11 Analysts recommend Moderna to buy, 17 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Moderna stock has an average upside potential 2027 of
20.95%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.94 | 2.14 |
| 39.93% | 10.08% | |
| EBITDA Margin | -132.10% | -149.64% |
| 31.09% | 13.28% | |
| Net Margin | -145.16% | -160.56% |
| 31.92% | 10.61% |
26 Analysts have issued a sales forecast Moderna 2026 . The average Moderna sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an Moderna EBITDA forecast 2026. The average Moderna EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
27 Moderna Analysts have issued a net profit forecast 2026. The average Moderna net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -7.25 | -8.61 |
| 21.79% | 18.76% | |
| P/E | negative | |
| EV/Sales | 25.06 |
27 Analysts have issued a Moderna forecast for earnings per share. The average Moderna EPS is
This results in the following potential growth metrics and future valuations:
Current Moderna Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Rothschild & Co |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| Argus Research |
Locked
➜
Locked
|
Locked | Aug 28 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 24 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 21 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Rothschild & Co:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
Argus Research:
Locked
➜
Locked
|
Aug 28 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 24 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 21 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 20 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
